secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001193125-23-149353
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics CSO Dr. Lisa Olson departs effective May 15, 2023 amid proposed merger with Dianthus
--------------------------------------------------------------------------------

- Dr. Lisa Olson, Head of Research and CSO, left Magenta on May 15, 2023 due to completion of certain asset sales and announced proposed merger with Dianthus.
- Magenta entered into a consulting agreement with Dr. Olson for work on an as-requested basis at an hourly rate.
- Dr. Olson is eligible for severance benefits under her amended employment agreement, subject to execution of a separation agreement.
- The departure is part of restructuring related to the proposed merger with Dianthus Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523149353/0001193125-23-149353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523149353/d469753d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-149353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer